Suppr超能文献

人脐带间充质干细胞:干细胞治疗的新时代。

Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy.

作者信息

Ding Dah-Ching, Chang Yu-Hsun, Shyu Woei-Cherng, Lin Shinn-Zong

机构信息

Department of Obstetrics and Gynecology, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan.

出版信息

Cell Transplant. 2015;24(3):339-47. doi: 10.3727/096368915X686841. Epub 2015 Jan 23.

Abstract

The human umbilical cord is a promising source of mesenchymal stem cells (HUCMSCs). Unlike bone marrow stem cells, HUCMSCs have a painless collection procedure and faster self-renewal properties. Different derivation protocols may provide different amounts and populations of stem cells. Stem cell populations have also been reported in other compartments of the umbilical cord, such as the cord lining, perivascular tissue, and Wharton's jelly. HUCMSCs are noncontroversial sources compared to embryonic stem cells. They can differentiate into the three germ layers that promote tissue repair and modulate immune responses and anticancer properties. Thus, they are attractive autologous or allogenic agents for the treatment of malignant and nonmalignant solid and soft cancers. HUCMCs also can be the feeder layer for embryonic stem cells or other pluripotent stem cells. Regarding their therapeutic value, storage banking system and protocols should be established immediately. This review critically evaluates their therapeutic value, challenges, and future directions for their clinical applications.

摘要

人脐带是间充质干细胞(HUCMSCs)的一个有前景的来源。与骨髓干细胞不同,HUCMSCs的采集过程无痛且自我更新特性更快。不同的衍生方案可能会提供不同数量和群体的干细胞。在脐带的其他部分,如脐带内衬、血管周围组织和华通氏胶中也报道了干细胞群体。与胚胎干细胞相比,HUCMSCs是无争议的来源。它们可以分化为促进组织修复、调节免疫反应和抗癌特性的三个胚层。因此,它们是治疗恶性和非恶性实体癌及软组织癌的有吸引力的自体或同种异体药物。HUCMCs也可以作为胚胎干细胞或其他多能干细胞的饲养层。关于它们的治疗价值,应立即建立储存库系统和方案。本综述批判性地评估了它们的治疗价值、挑战以及临床应用的未来方向。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验